Navigation Links
A large subgroup of mild-to-moderate asthma is persistently non-eosinophilic
Date:1/5/2012

A large percentage of patients with mild-to-moderate asthma have persistently non-eosinophilic disease which may not respond to currently available anti-inflammatory treatments, according to a new study.

In a cross-sectional study of 995 asthmatic subjects enrolled in nine clinical trials conducted by the NHLBI's Asthma Clinical Research Network, sputum eosinophilia (≥2% eosinophils) was found in only 36% of asthmatics not using an inhaled corticosteroid (ICS) and 17% of those using an ICS. Among patients who achieved good asthma control, 26% had sputum eosinophilia, compared with 15% among patients who had not achieved good control.

The findings were published online ahead of print publication in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

Among asthmatic subjects not taking an ICS who had repeated induced sputum samples, 22% had sputum eosinophilia on every occasion (persistent eosinophilia), 31% had eosinophilia on at least one occasion (intermittent eosinophilia), and 47% had no eosinophilia on every occasion (persistently non-eosinophilic). Two weeks of treatment with a combination of anti-inflammatory drugs resulted in significant improvements in airflow obstruction in subjects with eosinophilic asthma, but not in those with persistently non- eosinophilic asthma. Bronchodilator responses to albuterol, however, were similar in eosinophilic and non-eosinophilic asthma.

"Prevalence estimates for non-eosinophilic asthma in earlier studies were based on single sputum samples," said John Fahy, MD, MSc, professor of medicine and director of the Cardiovascular Research Institute/University of California San Francisco Airway Clinical Research Center. "Here we show for the first time that sputum eosinophilia is persistently absent in a large percentage of patients with mild/moderate asthma when sputum is analyzed repeatedly over time."

The poor response to intense combined treatment seen in patients with persistently non-eosinophilic asthma suggests that these patients have a unique disease phenotype for which new treatments need to be developed. Treatment responses in patients with intermittent eosinophilia were similar to those of patients with persistent eosinophilia.

"A large subgroup of patients with mild-to-moderate asthma do not have the usual eosinophilic subtype that is responsive to steroid treatment," concluded Dr. Fahy. "In addition to the implications for the care of these patients, our results have important implications for future asthma research. In clinical studies, the eosinophil phenotype of patients should be characterized to better understand treatment responses and disease mechanisms. In addition, appropriate in vitro and animal models for the study of the mechanisms of non-eosinophilic airway disease need to be developed."


'/>"/>
Contact: Nathaniel Dunford
ndunford@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. New evidence that bacteria in large intestine have a role in obesity
2. NDAR federation creates largest source of autism research data to date
3. Nations largest federation of biological and biomedical organizations welcomes 2 new members
4. Spains digital gender gap is larger than European average
5. Save the date: National meeting of the worlds largest scientific society
6. Food served in childrens hospitals rated largely unhealthy
7. Study Finds Link Between Low IQ, Large Waistline
8. Large-scale jaw pain study sheds light on pain disorders
9. First large-scale study of pain reveals risk factors
10. Steps being taken towards achieving an early diagnosis of cancer of the large intestine
11. Larger Food Portions May Be Seen as Status Symbols
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... As renowned, board-certified dermatologists, Dr. Sabrina G. Fabi ... patients who do not do their research and undergo cosmetic dermatology treatments from unqualified ... midst of a renaissance and every other month a new treatment or device is ...
(Date:12/5/2016)... , ... December 05, 2016 , ... ... today that they have teamed up with The American College of Surgeons (ACS) ... ACS’s Committee on Trauma, the “Bleeding Control Basic” course is a pilot program ...
(Date:12/4/2016)... (PRWEB) , ... December 03, 2016 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... hosted its first Swirl: A Wine Tasting Event in New York City, with ...
(Date:12/4/2016)... ... December 03, 2016 , ... Houston ... the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine ... Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, ...
(Date:12/4/2016)... (PRWEB) , ... December 04, 2016 , ... ... undergoing major cosmetic surgery can now take advantage of a cosmetic procedure known ... skin rejuvenation treatment that reduces the appearance of age spots, fine lines, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... December 5, 2016 PharmaBoardroom today releases its new ... ... This report offers companies, investors, policymakers, and stakeholders crucial insight into ... Europe , home to some of the world,s most important ... in Novartis and Roche, and with a number one ranking globally in ...
(Date:12/4/2016)... CAMBRIDGE, Mass. , Dec. 4, 2016 /PRNewswire/ ... a leader in discovering and developing targeted kinase ... announced data from its ongoing Phase 1 trial ... of patients with advanced systemic mastocytosis (SM). Blueprint ... selective inhibitor of D816V mutant KIT. Approximately 90 ...
(Date:12/4/2016)... Dec. 3, 2016 Sickle cell disease (SCD) ... red blood cells that get stuck in veins and ... organ failure, and complications leading to death. Each year, ... SCD, and most of them lack access to comprehensive ... established long-term therapy for SCD, a pill called hydroxyurea ...
Breaking Medicine Technology: